Drug-eluting stents are quickly replacing bare-metal stents as the arterial revascularization device of choice. Because nearly all of the information we have about patient outcomes with drug-eluting stents is from trials designed for U.S. Food and Drug Administration approval, we are missing some of the information critical to a more comprehensive understanding of how these new devices will perform at the population level.